Monrovia, CA -- (SBWIRE) -- 10/06/2011 -- John H Rex, Vice President at AstraZeneca and David J. Payne, Vice President at GlaxoSmithKline will give keynote presentations at the 8th Anti-infectives Partnering and Deal-making Conference to be held in Boston, MA on November 7-8, 2011 by GTC.
John H. Rex will give a keynote speech on “Evaluating Antibacterial Opportunities: Practical Advice” and David J. Payne will his keynote speech on “Approaches for Overcoming the Challenges of Antibacterial R&D.”
The sessions for the conferences are:
Session I - Recent Advances in Anti-Infectives Development - Part I - Anti-bacterial
Session II - Novel Technologies in Anti-Infectives
Panel Discussion - Investments and Partnerships in the Anti-Infectives Space
Session III - Recent Advances in Anti-Infectives Development - Part II
Session IV - Regulatory Updates
Session V - Innovative Partnering & Licensing Strategies
Session VI - Current Models of Deals in Infectious Diseases
Dr. Rex participated in a variety of clinical trials that investigate the utility of new antifungal agents in human infection. His work in this area has focused primarily on invasive fungal infections of the critically-ill non-neutropenic adult. Also Dr. Rex's laboratory is involved in a variety of studies on the technical aspects of in vitro susceptibility testing. He is a member of the National Committee for Clinical Laboratory Standards' Antifungal Susceptibility Testing Subcommittee. Through the work done in his laboratory with this committee, he has had the opportunity to participate in the development of the M27 and M38 documents on susceptibility testing of yeasts and moulds, respectively. His laboratory uses animal models of invasive fungal infections to investigate better ways to treat these infections in humans. He and colleagues investigate both new drugs and new ways to better use old drugs. These studies are often directly tied to better understanding of ways to use in vitro susceptibility testing to predict response to infection.
Dr. Payne has 21 years of experience in antibacterial drug discovery and is currently Vice
President and Head of the Antibacterial Discovery Performance Unit (DPU) within the Infectious Diseases Centre of Excellence in Drug Discovery (ID CEDD) where he is responsible for GSK’s antibacterial research effort from discovery to clinical proof of concept (up to Phase II clinical trials). At GSK, Dr Payne has played a leading role in redesigning the strategy for antibacterial research and has helped create long-term alliances with innovative biotechnology companies which has expanded GSK’s discovery pipeline. Furthermore, he has created industry-leading partnerships with the Wellcome Trust and the Defense Threat Reduction Agency (US Department of Defense) to accelerate GSK’s antibacterial programmes. To date, Dr Payne has been involved with the progression of a broad diversity of novel mechanism antibacterial agents into development.
The 8th Anti-infectives Partnering and Deal-making Conference gives global biotechnology and pharmaceutical companies in the infectious diseases industry an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant infectious disease issues and partnerships that will affect the industry.
The conference is part of the Infectious Diseases World Summit, which consists of 2 tracks including the 9th Vaccines Discovery and Development: All Things Considered Conference.